摘要
胰腺癌恶性程度高,起病隐匿,早期诊断困难。早期胰腺癌以手术为首选治疗方式,但易复发。进展期胰腺癌对放疗不敏感,只能进行以化疗为主的全身综合治疗。吉西他滨是目前标准胰腺癌化疗的一线治疗药物,但治疗效果不能满足临床需求,新型靶向治疗药物是研究热点。文中介绍针对不同信号转导通路的分子靶向药物对胰腺癌的治疗机制及效果,如表皮生长因子受体单克隆抗体及酪氨酸激酶抑制剂,阻断细胞信号转导途径,抑制肿瘤细胞的转移,促进肿瘤细胞凋亡;靶向血管内皮生长因子受体的药物抑制肿瘤血管生成和转移;还有胰岛素样生长因子受体拮抗剂、人源死亡受体5(death receptor 5,DR5)单抗诱导细胞凋亡等。
Pancreatic cancer is one of the most malignant tumors with concealed pathogenesis,rapid progress and poor prognosis.The best treatment for early pancreatic cancer is surgery.However,for metastasize pancreatic cancer,chemotherapy is the main treatment.Gemcitabine has been a standard treatment for advanced pancreatic cancer,but the therapeutic efficacy is not optimistic.As a result,finding effective novel molecular targeted drugs is the hot spot.This review focused on the present study and advances in molecular target therapy,introducing mechanism and efficacy of some novel drugs through different signal pathways.For example,inhibitors of epidermal growth factor receptor block the activation of the receptors or decrease the activity of tyrosine kinases,which can inhibit metastasis and increase apoptosis of tumor cells;VEGFR antagonists or antibodies reduce angiogenesis;IGF-1R antagonist,DR5 antibodies and so on are also included.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2010年第19期1767-1770,共4页
Chinese Journal of New Drugs
关键词
胰腺癌
分子靶向治疗
吉西他滨
pancreatic cancer
molecular targeted drugs
gemcitabine
